Cytokinetics Incorporated [NASDAQ: CYTK] closed the trading session at $22.82 on 03/12/21. The day’s price range saw the stock hit a low of $20.66, while the highest price level was $22.84. The company report on March 3, 2021 that Cytokinetics to Participate in Upcoming Investor Conferences.
Cytokinetics, Incorporated (Nasdaq: CYTK) announced that Robert I. Blum, President and Chief Executive Officer, is scheduled to present at the virtual H.C. Wainwright Global Life Sciences Conference taking place March 9-10, 2021 and participate in a fireside chat at the virtual Barclays Global Healthcare Conference on March 11, 2021 at 9:45 AM ET.
Interested parties may access the pre-recorded presentation from the H.C. Wainwright Global Life Sciences Conference and the live webcast of the fireside chat from the Barclays Global Healthcare Conference by visiting the Investors & Media section of the Cytokinetics website at www.cytokinetics.com. The replay of each presentation will be archived on the Presentations page within the Investors & Media section of Cytokinetics’ website for 90 days following the conclusion of the event.
The stocks have a year to date performance of 9.82 percent and weekly performance of 15.96 percent. The stock has been moved at 0.13 percent over the last six months. The stock has performed -1.47 percent around the most recent 30 days and changed 11.48 percent over the most recent 3-months.
If compared to the average trading volume of 930.32K shares, CYTK reached to a volume of 1006338 in the most recent trading day, which is why market watchdogs consider the stock to be active.
Here’s what leading stock market gurus have to say about Cytokinetics Incorporated [CYTK]:
Based on careful and fact-backed analyses by Wall Street experts, the current consensus on the target price for CYTK shares is $27.10 per share. Analysis on target price and performance of stocks is usually carefully studied by market experts, and the current Wall Street consensus on CYTK stock is a recommendation set at 2.10. This rating represents a strong Buy recommendation, on the scale from 1 to 5, where 5 would mean strong sell, 4 represents Sell, 3 is Hold, and 2 indicates Buy.
Wolfe Research have made an estimate for Cytokinetics Incorporated shares, keeping their opinion on the stock as Outperform, with their previous recommendation back on March 12, 2021. While these analysts kept the previous recommendation, Barclays raised their target price to Overweight. The new note on the price target was released on February 18, 2021, representing the official price target for Cytokinetics Incorporated stock. Previously, the target price had yet another raise from $22 to $41, while H.C. Wainwright kept a Buy rating on CYTK stock.
The Average True Range (ATR) for Cytokinetics Incorporated is set at 1.38, with the Price to Sales ratio for CYTK stock in the period of the last 12 months amounting to 25.87. The Price to Book ratio for the last quarter was 12.97, with the Price to Cash per share for the same quarter was set at 7.34.
CYTK stock trade performance evaluation
Cytokinetics Incorporated [CYTK] gain into the green zone at the end of the last week, gaining into a positive trend and gaining by 15.96. With this latest performance, CYTK shares dropped by -1.47% in over the last four-week period, additionally plugging by 0.13% over the last 6 months – not to mention a rise of 118.58% in the past year of trading.
Overbought and oversold stocks can be easily traced with the Relative Strength Index (RSI), where an RSI result of over 70 would be overbought, and any rate below 30 would indicate oversold conditions. An RSI rate of 50 would represent a neutral market momentum. The current RSI for CYTK stock in for the last two-week period is set at 63.04, with the RSI for the last a single of trading hit 70.15, and the three-weeks RSI is set at 59.45 for Cytokinetics Incorporated [CYTK]. The present Moving Average for the last 50 days of trading for this stock 20.67, while it was recorded at 20.34 for the last single week of trading, and 20.96 for the last 200 days.
Cytokinetics Incorporated [CYTK]: An insightful look at the core fundamentals
Operating Margin for any stock indicates how profitable investing would be, and Cytokinetics Incorporated [CYTK] shares currently have an operating margin of -168.27. Cytokinetics Incorporated’s Net Margin is presently recorded at -228.00.
Return on Total Capital for CYTK is now -49.84, given the latest momentum, and Return on Invested Capital for the company is -68.88. Return on Equity for this stock declined to -248.50, with Return on Assets sitting at -30.91. When it comes to the capital structure of this company, Cytokinetics Incorporated [CYTK] has a Total Debt to Total Equity ratio set at 122.15. Additionally, CYTK Total Debt to Total Capital is recorded at 54.99, with Total Debt to Total Assets ending up at 25.95. Long-Term Debt to Equity for the company is recorded at 119.69, with the Long-Term Debt to Total Capital now at 53.88.
Reflecting on the efficiency of the workforce at the company, Cytokinetics Incorporated [CYTK] managed to generate an average of -$691,793 per employee. Receivables Turnover for the company is 11.65 with a Total Asset Turnover recorded at a value of 0.14.Cytokinetics Incorporated’s liquidity data is similarly interesting compelling, with a Quick Ratio of 15.20 and a Current Ratio set at 15.20.
Earnings per share (EPS) analysis for Cytokinetics Incorporated [CYTK] stock
With the latest financial reports released by the company, Cytokinetics Incorporated posted -0.66/share EPS, while the average EPS was predicted by analysts to be reported at -0.5/share. When compared, the two values demonstrate that the company fail the estimates by a Surprise Factor of -32.00%. The progress of the company may be observed through the prism of EPS growth rate, while Wall Street analysts are focusing on predicting the 5-year EPS growth rate for CYTK. When it comes to the mentioned value, analysts are expecting to see the 5-year EPS growth rate for Cytokinetics Incorporated go to 15.00%.
Cytokinetics Incorporated [CYTK]: Insider Ownership positions
There are presently around $1,664 million, in the hands of institutional investors. The top three institutional holders of CYTK stocks are: BLACKROCK INC. with ownership of 11,611,079, which is approximately 7.91% of the company’s market cap and around 1.20% of the total institutional ownership; BVF INC/IL, holding 4,878,035 shares of the stock with an approximate value of $111.32 million in CYTK stocks shares; and VANGUARD GROUP INC, currently with $110.04 million in CYTK stock with ownership of nearly -2.867% of the company’s market capitalization.
Positions in Cytokinetics Incorporated stocks held by institutional investors increased at the end of February and at the time of the February reporting period, where 96 institutional holders increased their position in Cytokinetics Incorporated [NASDAQ:CYTK] by around 19,930,825 shares. Additionally, 100 investors decreased positions by around 16,125,216 shares, while 23 investors held positions by with 36,861,262 shares. The mentioned changes placed institutional holdings at 72,917,303 shares, according to the latest SEC report filing. CYTK stock had 38 new institutional investments in for a total of 14,171,447 shares, while 43 institutional investors sold positions of 6,460,419 shares during the same period.